Related Experiment Video
Updated: Apr 5, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
QT interval prolongation and cardiotoxicity in shorter regimens for rifampicin-resistant tuberculosis
Yilin Zhang1, Yang Li1, Yuanyuan Chen2
1National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China; Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Shanghai Sci-Tech Inno Center for Infection & Immunity, Shanghai, China.
Objectives:
Effective rifampicin-resistant tuberculosis (RR-TB) regimens often include multiple QT-prolonging drugs, necessitating evaluation across different combinations.
Methods:
Using pooled electrocardiogram data from two trials, three QT-prolonging shorter regimens for RR-TB were studied: the injectable-containing regimen comprising moxifloxacin and clofazimine (Mfx/Cfz), a levofloxacin-based regimen with clofazimine (Lfx/Cfz), and a bedaquiline-containing regimen with clofazimine (Bdq/Cfz). The prevalence and severity of corrected QT interval (QTc) prolongation between regimens were compared, and risk factors were evaluated.
Results:
Among 410 RR-TB participants, significant QTc prolongation was reported in 48.4% (78/161) of participants receiving the Mfx/Cfz regimen, 31.1% (51/164) receiving the Lfx/Cfz regimen, and 34.1% (29/85) receiving the Bdq/Cfz regimen. Nearly half of the significant QTc prolongation events occurred within 4 months of treatment. Seven episodes of symptomatic arrhythmia were documented. Compared with the Lfx/Cfz regimen, the Mfx/Cfz regimen was associated with an increased risk of significant QTc prolongation (adjusted hazard ratio 1.45, 95% confidence interval 1.01-2.07, P = 0.044). Additionally, pre-existing thyroid disease, cavitation, and older age were identified as independent risk factors of significant QTc prolongation.
Conclusion:
The Mfx/Cfz combination was associated with an elevated risk of QTc prolongation. Close electrocardiogram monitoring throughout the entire treatment course is advised in patients receiving such combination.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

